Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors - PubMed
- ️Sat Jan 01 2005
. 2005 Jul 22;280(29):26729-34.
doi: 10.1074/jbc.C500186200. Epub 2005 Jun 2.
Michael Pranpat, James Bradner, Maria Balasis, Warren Fiskus, Fei Guo, Kathy Rocha, Sandhya Kumaraswamy, Sandhya Boyapalle, Peter Atadja, Edward Seto, Kapil Bhalla
Affiliations
- PMID: 15937340
- DOI: 10.1074/jbc.C500186200
Free article
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors
Purva Bali et al. J Biol Chem. 2005.
Free article
Abstract
The hydroxamic acid (HAA) analogue pan-histone deacetylase (HDAC) inhibitors (HDIs) LAQ824 and LBH589 have been shown to induce acetylation and inhibit the ATP binding and chaperone function of heat shock protein (HSP) 90. This promotes the polyubiquitylation and degradation of the pro-growth and pro-survival client proteins Bcr-Abl, mutant FLT-3, c-Raf, and AKT in human leukemia cells. HDAC6 is a member of the class IIB HDACs. It is predominantly cytosolic, microtubule-associated alpha-tubulin deacetylase that is also known to promote aggresome inclusion of the misfolded polyubiquitylated proteins. Here we demonstrate that in the Bcr-abl oncogene expressing human leukemia K562 cells, HDAC6 can be co-immunoprecipitated with HSP90, and the knock-down of HDAC6 by its siRNA induced the acetylation of HSP90 and alpha-tubulin. Depletion of HDAC6 levels also inhibited the binding of HSP90 to ATP, reduced the chaperone association of HSP90 with its client proteins, e.g. Bcr-Abl, and induced polyubiquitylation and partial depletion of Bcr-Abl. Conversely, the ectopic overexpression of HDAC6 inhibited LAQ824-induced acetylation of HSP90 and alpha-tubulin and reduced LAQ824-mediated depletion of Bcr-Abl, AKT, and c-Raf. Collectively, these findings indicate that HDAC6 is also an HSP90 deacetylase. Targeted inhibition of HDAC6 leads to acetylation of HSP90 and disruption of its chaperone function, resulting in polyubiquitylation and depletion of pro-growth and pro-survival HSP90 client proteins including Bcr-Abl. Depletion of HDAC6 sensitized human leukemia cells to HAA-HDIs and proteasome inhibitors.
Similar articles
-
Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, Rao R, Herger B, Yang Y, Atadja P, Wu J, Bhalla K. Fiskus W, et al. Clin Cancer Res. 2007 Aug 15;13(16):4882-90. doi: 10.1158/1078-0432.CCR-06-3093. Clin Cancer Res. 2007. PMID: 17699868
-
Rao R, Fiskus W, Yang Y, Lee P, Joshi R, Fernandez P, Mandawat A, Atadja P, Bradner JE, Bhalla K. Rao R, et al. Blood. 2008 Sep 1;112(5):1886-93. doi: 10.1182/blood-2008-03-143644. Epub 2008 Jun 30. Blood. 2008. PMID: 18591380
-
George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K. George P, et al. Blood. 2005 Feb 15;105(4):1768-76. doi: 10.1182/blood-2004-09-3413. Epub 2004 Oct 28. Blood. 2005. PMID: 15514006
-
Drugging the HDAC6-HSP90 interplay in malignant cells.
Krämer OH, Mahboobi S, Sellmer A. Krämer OH, et al. Trends Pharmacol Sci. 2014 Oct;35(10):501-9. doi: 10.1016/j.tips.2014.08.001. Epub 2014 Sep 16. Trends Pharmacol Sci. 2014. PMID: 25234862 Review.
-
Liu P, Xiao J, Wang Y, Song X, Huang L, Ren Z, Kitazato K, Wang Y. Liu P, et al. Mol Med. 2021 Sep 16;27(1):110. doi: 10.1186/s10020-021-00375-3. Mol Med. 2021. PMID: 34530730 Free PMC article. Review.
Cited by
-
Wilson PM, Labonte MJ, Martin SC, Kuwahara ST, El-Khoueiry A, Lenz HJ, Ladner RD. Wilson PM, et al. Invest New Drugs. 2013 Aug;31(4):845-57. doi: 10.1007/s10637-012-9914-7. Epub 2013 Jan 9. Invest New Drugs. 2013. PMID: 23299388
-
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma.
Tandon N, Ramakrishnan V, Kumar SK. Tandon N, et al. Clin Pharmacol. 2016 May 6;8:35-44. doi: 10.2147/CPAA.S94021. eCollection 2016. Clin Pharmacol. 2016. PMID: 27226735 Free PMC article. Review.
-
Zhang J, Junigan JM, Trinh R, Kavelaars A, Heijnen CJ, Grace PM. Zhang J, et al. J Neurosci. 2022 Oct 19;42(42):7862-7874. doi: 10.1523/JNEUROSCI.1182-22.2022. Epub 2022 Sep 12. J Neurosci. 2022. PMID: 36096670 Free PMC article.
-
Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, Lee SJ. Kim SH, et al. Endocrine. 2016 Feb;51(2):274-82. doi: 10.1007/s12020-015-0706-7. Epub 2015 Jul 29. Endocrine. 2016. PMID: 26219406
-
Stochasticity of anticancer mechanisms underlying clinical effectiveness of vorinostat.
El Omari N, Khalid A, Makeen HA, Alhazmi HA, Albratty M, Mohan S, Tan CS, Ming LC, Chook JB, Bouyahya A. El Omari N, et al. Heliyon. 2024 Jun 18;10(12):e33052. doi: 10.1016/j.heliyon.2024.e33052. eCollection 2024 Jun 30. Heliyon. 2024. PMID: 39021957 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous